| Formulary Chapter 13: Skin - Full Chapter
|
| Notes: |
Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.
Formulary approved "off-label" use is detailed separately. |
|
| Details... |
| 13.08.01 |
Sunscreen preparations |
|
|
Anthelios XL® melt in cream (Sunscreen SPF 50+)
(ACBS)
|
Formulary
|
 Approved for prescribing for (ACBS):
Protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo, and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis
|
|
|
Sunsense® Ultra (Sunscreen SPF 50+)
(ACBS)
|
Formulary
|
Approved for prescribing for (ACBS):
Protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo, and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis
|
|
|
Reflective (Dundee) sunscreens - coffee, coral, pink, beige
|
 Unlicensed
|
BAD/APC approved Special
For photosensitivity disorders where the patient is sensitive to visible light, most commonly solar urticaria and porphyrias, particularly erythropoietic protoporphyria.
|
|
|
| 13.08.01 |
Photodamage |
|
|
Diclofenac sodium gel 3% (Solaraze®)
|
Formulary
|
|
|
|
Fluorouracil cream 5% (Efudix®)
|
Formulary
|
To treat actinic keratosis and basal cell carcinoma of the skin.
Apply once or twice a day
|
|
|
Ingenol mebutate 150 micrograms/g, 500 micrograms/g (Picato®)
|
Formulary
|
For treating actinic keratosis with small areas of field change up to a maximum of 25cm2
GPs should not re-treat patients who have a recurrence on the same skin area - to refer to secondary care for re-evaluation due to the small risk of progression to squamous cell carcinoma.
|
 SE London APC recommendation: Ingenol for non-hyperkeratotic, nonhypertrophic AK in adults.
|
Methyl-5-aminolevulinate cream (Metvix®)
|
Formulary
|
USE UNDER SPECIALIST SUPERVISION ONLY
Treatment of actinic keratoses, superficial or nodular basal cell carcinoma and Bowen's Disease.
|
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|
|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |
|
Specialist initiation followed by maintenance prescribing in primary care |
|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |
|
Specialist and non-specialist initiation |
|
Not recommended for prescribing |
|
|
|
